|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Human bladder cancer T24 and 5637 cell lines were transiently transfected with FGFR3-AS1-specific siRNA or negative control siRNA.
|
29226855 |
2018 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
|
16278395 |
2005 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
In contrast, there are very few studies on the impact of miRNA regulation on signaling by VHL (von Hippel-Lindau tumor suppressor) and vascular endothelial growth factor in renal cell carcinoma or by fibroblast growth factor receptor 3 and p53 in bladder cancer.
|
21632885 |
2011 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggested for the first time that fluazuron is a potential inhibitor of FGFR3 and a candidate anticancer drug for the treatment of BC.
|
27664399 |
2017 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations of FGFR3 have been identified in bladder cancer, multiple myeloma, and other neoplasms.
|
16778799 |
2006 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we show that HDAC6 loss or inhibition reduces FGFR3 accumulation in cells made tumorigenic by ectopic expression of a mutant activated version of FGFR3 together with the MYC oncoprotein and in a bladder cancer cell line whose tumorigenicity is dependent on expression of a translocated version of FGFR3.
|
29423038 |
2018 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of FGFR3 are a common and early event in bladder cancer.
|
25223521 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activating point mutations and protein overexpression of fibroblast growth factor receptors (FGFRs), especially FGFR3, are frequent events in bladder cancer.
|
24898159 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer.
|
26901314 |
2016 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
|
28049011 |
2017 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
|
25809917 |
2015 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
These studies provide in vivo evidence demonstrating an oncogenic role of FGFR3 in bladder cancer and support antibody-based targeting of FGFR3 in hematologic and epithelial cancers driven by WT or mutant FGFR3.
|
19381019 |
2009 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
|
18413799 |
2008 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In view of these findings, the authors investigated the incidence of TD mutations in the FGFR3 gene in a large series of bladder carcinomas to clarify their role in the progression of bladder carcinoma.
|
11745189 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma.
|
11466624 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours.
|
23272046 |
2012 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In non-invasive BC, these mutations were related to high risk and grade (p<0.0001) as well as progression to muscle-invasive disease (p=0.01), whereas FGFR3 mutations were observed in low-grade BC (p=0.02) and patients with recurrences (p=0.05).
|
27611947 |
2016 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
As for FGFR3 in UCC, tumors with high FOXA1 expression have lower rates of progression than those with low expression (Log rank p=0.009).
|
25071007 |
2014 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
|
27356691 |
2016 |
|
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR).
|
30977669 |
2019 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer.
|
16061860 |
2005 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Conversely, FGFR3 over-expression was recently found in 40 % of muscle invasive BC.
|
24880661 |
2014 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PATIENT SUMMARY: We propose that APOBEC-mediated mutagenesis can generate clinically relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3 S249C, one of the most common mutations in bladder cancer.
|
30975452 |
2019 |
|
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We discovered a positive feedback loop, in which the activation of p38 and AKT downstream from the altered FGFR3 upregulates <i>MYC</i> mRNA levels and stabilizes MYC protein, respectively, leading to the accumulation of MYC, which directly upregulates <i>FGFR3</i> expression by binding to active enhancers upstream from <i>FGFR3</i> Disruption of this FGFR3/MYC loop in bladder cancer cell lines by treatment with FGFR3, p38, AKT, or BET bromodomain inhibitors (JQ1) preventing <i>MYC</i> transcription decreased cell viability <i>in vitro</i> and tumor growth <i>in vivo</i> A relevance of this loop to human bladder tumors was supported by the positive correlation between <i>FGFR3</i> and <i>MYC</i> levels in tumors bearing <i>FGFR3</i> mutations, and the decrease in FGFR3 and MYC levels following anti-FGFR treatment in a PDX model bearing an <i>FGFR3</i> mutation.
|
29463565 |
2018 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic FGFR3 gene fusions in bladder cancer.
|
23175443 |
2013 |